Association of Interleukin-17 Inhibitors With Hypertension in Patients With Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials

J Cardiovasc Pharmacol. 2024 Jun 1;83(6):557-564. doi: 10.1097/FJC.0000000000001547.
No abstract available

Publication types

  • Systematic Review
  • Meta-Analysis
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / therapeutic use
  • Autoimmune Diseases* / drug therapy
  • Autoimmune Diseases* / immunology
  • Blood Pressure / drug effects
  • Humans
  • Hypertension* / drug therapy
  • Hypertension* / immunology
  • Hypertension* / physiopathology
  • Interleukin-17* / antagonists & inhibitors
  • Interleukin-17* / immunology
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antihypertensive Agents
  • IL17A protein, human
  • Interleukin-17